ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million

Core Insights - ASSET PLANNING SERVICES INC /LA/ /ADV has completely divested its position in Pfizer, selling all 109,630 shares for an estimated $2.66 million, reducing its holding to zero as of September 30, 2025 [2][3][6] Company Overview - As of October 16, 2025, Pfizer's share price was $24.27, with a year-to-date decline of 8.5% and underperforming the S&P 500 by 21 percentage points [3][4] - Pfizer's dividend yield stands at 7.05%, indicating a consistent return to shareholders despite recent stock performance challenges [4] Market Context - The exit from Pfizer may reflect a broader trend among investors seeking stronger growth opportunities in sectors like technology and finance, as evidenced by the fund's increased focus on companies like NVIDIA and Microsoft [6][9] - Pfizer continues to face challenges in the post-pandemic landscape, including decreased COVID-related revenues and heightened competition in its vaccine and therapeutic markets [6][9] Investment Implications - The fund's shift away from Pfizer suggests a growing confidence in innovation and capital markets over traditional healthcare investments, although long-term investors may view Pfizer's current weakness as a potential buying opportunity due to its strong drug pipeline and dividend yield [9]